Literature DB >> 17112233

Cell growth inhibition and actin cytoskeleton disorganization induced by azaspiracid-1 structure-activity studies.

Natalia Vilariño1, K C Nicolaou, Michael O Frederick, Eva Cagide, Isabel R Ares, M Carmen Louzao, Mercedes R Vieytes, Luis M Botana.   

Abstract

Azaspiracid-1 (AZA-1) is a marine toxin discovered 10 years ago. Since then, toxicologic studies have demonstrated that AZA-1 targets several organs in vivo, including the intestine, lymphoid tissues, lungs, and nervous system; however, the mechanism of action of AZA-1 remains unknown. Studies in vitro suggest that AZA-1 affects the actin cytoskeleton in nonadherent cells. We characterized the effects of AZA-1 on the cytoskeleton of adherent cells and on cell growth, an adhesion-dependent process in many cell types, and analyzed the structure dependency of this toxicity. Confocal and TIRF imaging of fluorescently labeled cytosketon showed that AZA-1 induced the rearrangement of stress fibers (actin filament bundles) and the loss of focal adhesion points in neuroblastoma and Caco-2 cells, without affecting the amount of polymerized actin. AZA-1 did not seem to alter the microtubule cytoskeleton, but it changed the cell shape and internal morphology observed by phase contrast imaging. Cell growth of lung carcinoma and neuroblastoma cells was inhibited by the toxin, as measured by a sulforhodamine B assay and BrdU incorporation to newly synthesized DNA. Fifteen different fragments and/or stereoisomers of AZA-1 were tested for cytoskeletal rearrangement and cell growth inhibition. Results showed that no fragment or stereoisomer had any activity, except for ABCD-epi-AZA-1, which conserved toxicity. AZA-1-induced reorganization of the actin cytoskeleton concurred with detachment and growth inhibition, three events that are probably related.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17112233     DOI: 10.1021/tx060131z

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  7 in total

Review 1.  Constructing molecular complexity and diversity: total synthesis of natural products of biological and medicinal importance.

Authors:  K C Nicolaou; Christopher R H Hale; Christian Nilewski; Heraklidia A Ioannidou
Journal:  Chem Soc Rev       Date:  2012-06-28       Impact factor: 54.564

2.  Subacute Cardiovascular Toxicity of the Marine Phycotoxin Azaspiracid-1 in Rats.

Authors:  Sara F Ferreiro; Natalia Vilariño; Cristina Carrera; M Carmen Louzao; Antonio G Cantalapiedra; Germán Santamarina; J Manuel Cifuentes; Andrés C Vieira; Luis M Botana
Journal:  Toxicol Sci       Date:  2016-02-10       Impact factor: 4.849

3.  Azaspiracid substituent at C1 is relevant to in vitro toxicity.

Authors:  Natalia Vilariño; K C Nicolaou; Michael O Frederick; Eva Cagide; Carmen Alfonso; Eva Alonso; Mercedes R Vieytes; Luis M Botana
Journal:  Chem Res Toxicol       Date:  2008-08-16       Impact factor: 3.739

4.  From nature to the laboratory and into the clinic.

Authors:  K C Nicolaou; Jason S Chen; Stephen M Dalby
Journal:  Bioorg Med Chem       Date:  2008-11-06       Impact factor: 3.641

5.  Marine algal toxin azaspiracid is an open-state blocker of hERG potassium channels.

Authors:  Michael J Twiner; Gregory J Doucette; Andrew Rasky; Xi-Ping Huang; Bryan L Roth; Michael C Sanguinetti
Journal:  Chem Res Toxicol       Date:  2012-08-10       Impact factor: 3.739

6.  Total synthesis of (+)-azaspiracid-1. An exhibition of the intricacies of complex molecule synthesis.

Authors:  David A Evans; Lisbet Kvaernø; Travis B Dunn; André Beauchemin; Brian Raymer; Jason A Mulder; Edward J Olhava; Martin Juhl; Katsuji Kagechika; David A Favor
Journal:  J Am Chem Soc       Date:  2008-12-03       Impact factor: 15.419

Review 7.  Azaspiracid shellfish poisoning: a review on the chemistry, ecology, and toxicology with an emphasis on human health impacts.

Authors:  Michael J Twiner; Nils Rehmann; Philipp Hess; Gregory J Doucette
Journal:  Mar Drugs       Date:  2008-05-07       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.